Pulmonary Arterial Hypertension Market Segmentation by Drug Class - Endothelin Receptor Antagonists | PDE-5 Inhibitors | Prostacyclin and Prostacyclin Analogs | SGC Stimulators
Industry: Healthcare
Published Date: November-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 250
Report ID: PMRREP33199
1. Executive Summary
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Pulmonary Arterial Hypertension Market
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ Bn)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background
4.1. Pulmonary Arterial Hypertension Market, by Key Countries
4.2. Pulmonary Arterial Hypertension Market Opportunity Assessment (US$ Bn)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Growth in Automation, By Country
4.5.3. Microneedle Drug Delivery Systems Markets Adoption Rate, By Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Microneedle Drug Delivery Systems Markets Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global Pulmonary Arterial Hypertension Market Demand Analysis 2017-2021 and Forecast, 2022-2032
6.1. Historical Market Analysis, 2017-2021
6.2. Current and Future Market Projections, 2022-2032
6.3. Y-o-Y Growth Trend Analysis
7. Global Pulmonary Arterial Hypertension Market Value Analysis 2017-2021 and Forecast, 2022-2032
7.1. Historical Market Value (US$ Bn) Analysis, 2017-2021
7.2. Current and Future Market Value (US$ Bn) Projections, 2022-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Drug Class, 2017-2021
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug Class, 2022-2032
8.3.1. Endothelin Receptor Antagonists (ERAs)
8.3.2. PDE-5 inhibitors
8.3.3. Prostacyclin and Prostacyclin Analogs
8.3.4. SGC Stimulators
8.4. Market Attractiveness Analysis By Microneedle Drug Delivery Systems
9. Global Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032, By Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis By Type, 2017-2021
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Type, 2022-2032
9.3.1. Branded
9.3.2. Generics
9.4. Market Attractiveness Analysis By Route of Administration
10. Global Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis By Route of Administration, 2017-2021
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Route of Administration, 2022-2032
10.3.1. Oral
10.3.2. Intravenous/ Subcutaneous
10.3.3. Inhalational
10.4. Market Attractiveness Analysis By Route of Administration
11. Global Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032, By Region
11.1. Introduction
11.2. Historical Market Size (US$ Bn) Analysis By Region, 2017-2021
11.3. Current Market Size (US$ Bn) & Analysis and Forecast By Region, 2022-2032
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. Asia Pacific
11.3.5. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032
12.1. Introduction
12.2. Pricing Analysis
12.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
12.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032
12.4.1. By Country
12.4.1.1. U.S.
12.4.1.2. Canada
12.4.2. By Drug Class
12.4.3. By Route of Administration
12.4.4. By Route of Administration
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Type
12.5.3. By Route of Administration
12.5.4. By Route of Administration
13. Latin America Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
13.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032
13.4.1. By Country
13.4.1.1. Brazil
13.4.1.2. Mexico
13.4.1.3. Rest of Latin America
13.4.2. By Drug Class
13.4.3. By Route of Administration
13.4.4. By Route of Administration
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Type
13.5.3. By Route of Administration
13.5.4. By Route of Administration
14. Europe Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
14.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032
14.4.1. By Country
14.4.1.1. Germany
14.4.1.2. France
14.4.1.3. U.K.
14.4.1.4. Italy
14.4.1.5. Spain
14.4.1.6. Russia
14.4.1.7. Rest of Europe
14.4.2. By Drug Class
14.4.3. By Route of Administration
14.4.4. By Route of Administration
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Type
14.5.3. By Route of Administration
14.5.4. By Route of Administration
15. Asia Pacific Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
15.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032
15.4.1. By Country
15.4.1.1. China
15.4.1.2. Japan
15.4.1.3. South Korea
15.4.1.4. India
15.4.1.5. Australia
15.4.1.6. Rest of Asia Pacific
15.4.2. By Drug Class
15.4.3. By Route of Administration
15.4.4. By Route of Administration
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Type
15.5.3. By Route of Administration
15.5.4. By Route of Administration
16. Middle East and Africa Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
16.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2022-2032
16.4.1. By Country
16.4.1.1. Saudi Arabia
16.4.1.2. South Africa
16.4.1.3. Israel
16.4.1.4. UAE
16.4.1.5. Rest of Middle East and Africa
16.4.2. By Drug Class
16.4.3. By Route of Administration
16.4.4. By Route of Administration
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Type
16.5.3. By Route of Administration
16.5.4. By Route of Administration
17. Key Countries Pulmonary Arterial Hypertension Market Analysis 2017-2021 and Forecast 2022-2032
17.1. Introduction
17.1.1. Market Value Proportion Analysis, By Key Countries
17.1.2. Global Vs. Country Growth Comparison
17.2. US Pulmonary Arterial Hypertension Market Analysis
17.2.1. Value Proportion Analysis by Market Taxonomy
17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.2.2.1. By Drug Class
17.2.2.2. By Route of Administration
17.2.2.3. By Route of Administration
17.3. Canada Pulmonary Arterial Hypertension Market Analysis
17.3.1. Value Proportion Analysis by Market Taxonomy
17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.3.2.1. By Type
17.3.2.2. By Route of Administration
17.3.2.3. By Route of Administration
17.4. Mexico Pulmonary Arterial Hypertension Market Analysis
17.4.1. Value Proportion Analysis by Market Taxonomy
17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.4.2.1. By Drug Class
17.4.2.2. By Route of Administration
17.4.2.3. By Route of Administration
17.5. Brazil Pulmonary Arterial Hypertension Market Analysis
17.5.1. Value Proportion Analysis by Market Taxonomy
17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.5.2.1. By Type
17.5.2.2. By Route of Administration
17.5.2.3. By Route of Administration
17.6. Germany Pulmonary Arterial Hypertension Market Analysis
17.6.1. Value Proportion Analysis by Market Taxonomy
17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.6.2.1. By Drug Class
17.6.2.2. By Route of Administration
17.6.2.3. By Route of Administration
17.7. France Pulmonary Arterial Hypertension Market Analysis
17.7.1. Value Proportion Analysis by Market Taxonomy
17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.7.2.1. By Drug Class
17.7.2.2. By Route of Administration
17.7.2.3. By Route of Administration
17.8. Italy Pulmonary Arterial Hypertension Market Analysis
17.8.1. Value Proportion Analysis by Market Taxonomy
17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.8.2.1. By Drug Class
17.8.2.2. By Route of Administration
17.8.2.3. By Route of Administration
17.9. India Pulmonary Arterial Hypertension Market Analysis
17.9.1. Value Proportion Analysis by Market Taxonomy
17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.9.2.1. By Drug Class
17.9.2.2. By Route of Administration
17.9.2.3. By Route of Administration
17.10. UK Pulmonary Arterial Hypertension Market Analysis
17.10.1. Value Proportion Analysis by Market Taxonomy
17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.10.2.1. By Type
17.10.2.2. By Route of Administration
17.10.2.3. By Route of Administration
17.11. Australia Pulmonary Arterial Hypertension Market Analysis
17.11.1. Value Proportion Analysis by Market Taxonomy
17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.11.2.1. By Drug Class
17.11.2.2. By Route of Administration
17.11.2.3. By Route of Administration
17.12. China Pulmonary Arterial Hypertension Market Analysis
17.12.1. Value Proportion Analysis by Market Taxonomy
17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.12.2.1. By Drug Class
17.12.2.2. By Route of Administration
17.12.2.3. By Route of Administration
17.13. Japan Pulmonary Arterial Hypertension Market Analysis
17.13.1. Value Proportion Analysis by Market Taxonomy
17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.13.2.1. By Drug Class
17.13.2.2. By Route of Administration
17.13.2.3. By Route of Administration
17.14. South Korea Pulmonary Arterial Hypertension Market Analysis
17.14.1. Value Proportion Analysis by Market Taxonomy
17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.14.2.1. By Drug Class
17.14.2.2. By Route of Administration
17.14.2.3. By Route of Administration
17.15. Israel Pulmonary Arterial Hypertension Market Analysis
17.15.1. Value Proportion Analysis by Market Taxonomy
17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.15.2.1. By Drug Class
17.15.2.2. By Route of Administration
17.15.2.3. By Route of Administration
17.16. South Africa Pulmonary Arterial Hypertension Market Analysis
17.16.1. Value Proportion Analysis by Market Taxonomy
17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.16.2.1. By Drug Class
17.16.2.2. By Route of Administration
17.16.2.3. By Route of Administration
17.17. UAE Pulmonary Arterial Hypertension Market Analysis
17.17.1. Value Proportion Analysis by Market Taxonomy
17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.17.2.1. By Drug Class
17.17.2.2. By Route of Administration
17.17.2.3. By Route of Administration
17.18. Spain Pulmonary Arterial Hypertension Market Analysis
17.18.1. Value Proportion Analysis by Market Taxonomy
17.18.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.18.2.1. By Drug Class
17.18.2.2. By Route of Administration
17.18.2.3. By Route of Administration
17.19. Russia Pulmonary Arterial Hypertension Market Analysis
17.19.1. Value Proportion Analysis by Market Taxonomy
17.19.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.19.2.1. By Drug Class
17.19.2.2. By Route of Administration
17.19.2.3. By Route of Administration
17.20. Saudi Arabia Pulmonary Arterial Hypertension Market Analysis
17.20.1. Value Proportion Analysis by Market Taxonomy
17.20.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
17.20.2.1. By Drug Class
17.20.2.2. By Route of Administration
17.20.2.3. By Route of Administration
17.21. Competition Landscape and Player Concentration in the Country
18. Market Structure Analysis
18.1. Market Analysis by Tier of Companies
18.2. Market Concentration
18.3. Market Share Analysis of Top Players
18.4. Market Presence Analysis
18.4.1. By Regional footprint of Players
18.4.2. Product footprint by Players
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive
19.3.1. United Therapeutics Corporation
19.3.1.1. Overview
19.3.1.2. Product Portfolio
19.3.1.3. Sales Footprint
19.3.1.4. Strategy Overview
19.3.2. Bayer
19.3.2.1. Overview
19.3.2.2. Product Portfolio
19.3.2.3. Sales Footprint
19.3.2.4. Strategy Overview
19.3.3. Johnson & Johnson
19.3.3.1. Overview
19.3.3.2. Product Portfolio
19.3.3.3. Sales Footprint
19.3.3.4. Strategy Overview
19.3.4. Novartis
19.3.4.1. Overview
19.3.4.2. Product Portfolio
19.3.4.3. Sales Footprint
19.3.4.4. Strategy Overview
19.3.5. Lupin Pharmaceuticals
19.3.5.1. Overview
19.3.5.2. Product Portfolio
19.3.5.3. Sales Footprint
19.3.5.4. Strategy Overview
19.3.6. Viatris Inc.
19.3.6.1. Overview
19.3.6.2. Product Portfolio
19.3.6.3. Sales Footprint
19.3.6.4. Strategy Overview
19.3.7. Sun Pharmaceutical Industries, Inc.
19.3.7.1. Overview
19.3.7.2. Product Portfolio
19.3.7.3. Sales Footprint
19.3.7.4. Strategy Overview
19.3.8. Teva Pharmaceutical Industries Ltd.
19.3.8.1. Overview
19.3.8.2. Product Portfolio
19.3.8.3. Sales Footprint
19.3.8.4. Strategy Overview
20. Assumptions and Acronyms Used
21. Research Methodology
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Table 1: Global Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2017 – 2021
Table 2: Global Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2022 – 2032
Table 3: Global Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2017 – 2021
Table 4: Global Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2022 – 2032
Table 5: Global Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2017 – 2021
Table 6: Global Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2022 – 2032
Table 7: Global Pulmonary Arterial Hypertension Market, By Region, 2017 – 2021
Table 8: Global Pulmonary Arterial Hypertension Market, By Region, 2022 – 2032
Table 9: North America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2017 – 2021
Table 10: North America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2022 – 2032
Table 11: North America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2017 – 2021
Table 12: North America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2022 – 2032
Table 13: North America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2017 – 2021
Table 14: North America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2022 – 2032
Table 15: North America Pulmonary Arterial Hypertension Market, By Country, 2017 – 2021
Table 16: North America Pulmonary Arterial Hypertension Market, By Country, 2022 – 2032
Table 17: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2017 – 2021
Table 18: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2022 – 2032
Table 19: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2017 – 2021
Table 20: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2022 – 2032
Table 21: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2017 – 2021
Table 22: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2022 – 2032
Table 23: Latin America Pulmonary Arterial Hypertension Market, By Country, 2017 – 2021
Table 24: Latin America Pulmonary Arterial Hypertension Market, By Country, 2022 – 2032
Table 25: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2017 – 2021
Table 26: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2022 – 2032
Table 27: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2017 – 2021
Table 28: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2022 – 2032
Table 29: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2017 – 2021
Table 30: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2022 – 2032
Table 31: Europe Pulmonary Arterial Hypertension Market, By Country, 2017 – 2021
Table 32: Europe Pulmonary Arterial Hypertension Market, By Country, 2022 – 2032
Table 33: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2017 – 2021
Table 34: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2022 – 2032
Table 35: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2017 – 2021
Table 36: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2022 – 2032
Table 37: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2017 – 2021
Table 38: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2022 – 2032
Table 39: Asia Pacific Pulmonary Arterial Hypertension Market, By Country, 2017 – 2021
Table 40: Asia Pacific Pulmonary Arterial Hypertension Market, By Country, 2022 – 2032
Table 41: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2017 – 2021
Table 42: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn), By Drug Class, 2022 – 2032
Table 43: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2017 – 2021
Table 44: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn), By Route of Administration, 2022 – 2032
Table 45: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2017 – 2021
Table 46: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn), By Type, 2022 – 2032
Table 47: MEA Pulmonary Arterial Hypertension Market, By Country, 2017 – 2021
Table 48: MEA Pulmonary Arterial Hypertension Market, By Country, 2022 – 2032
Table 49: Global Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Drug Class, 2017 - 2021
Table 50: Global Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032
Table 51: Global Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Type, 2017 - 2021
Table 52: Global Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Region, 2022 – 2032
Table 53: North America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Drug Class, 2017 - 2021
Table 54: North America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032
Table 55: North America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Type, 2017 – 2021
Table 56: North America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Country, 2022 – 2032
Table 57: Latin America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Drug Class, 2017 - 2021
Table 58: Latin America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032
Table 59: Latin America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Type, 2017 - 2021
Table 60: Latin America Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Country, 2022 – 2032
Table 61: Europe Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Drug Class, 2017 - 2021
Table 62: Europe Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032
Table 63: Europe Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Type, 2017 - 2021
Table 64: Europe Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Country, 2022 - 2032
Table 65: Asia Pacific Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Drug Class, 2017 - 2021
Table 66: Asia Pacific Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032
Table 67: Asia Pacific Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Type, 2017 - 2021
Table 68: Asia Pacific Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Country, 2022 – 2032
Table 69: MEA Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Drug Class, 2017 - 2021
Table 70: MEA Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032
Table 71: MEA Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Type, 2017 - 2021
Table 72: MEA Pulmonary Arterial Hypertension Market Incremental $ Opportunity, By Country, 2022 - 2032
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
Figure 1: Global Pulmonary Arterial Hypertension Market Value (US$ Bn) and Year-on-Year Growth, 2017-2032
Figure 2: Global Pulmonary Arterial Hypertension Market Absolute $ Historical Gain (2017 - 2021) and Opportunity (2022 – 2032), US$ Bn
Figure 3: Global Pulmonary Arterial Hypertension Market Share, By Drug Class, 2022 & 2032
Figure 4: Global Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Drug Class– 2022-2032
Figure 5: Global Pulmonary Arterial Hypertension Market Attractiveness Index, By Drug Class– 2022-2032
Figure 6: Global Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2022 & 2032
Figure 7: Global Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration– 2022-2032
Figure 8: Global Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration– 2022-2032
Figure 9: Global Pulmonary Arterial Hypertension Market Share, By Type, 2022 & 2032
Figure 10: Global Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032
Figure 11: Global Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration – 2022-2032
Figure 12: Global Pulmonary Arterial Hypertension Market Share, By Region, 2022 & 2032
Figure 13: Global Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Region – 2022-2032
Figure 14: Global Pulmonary Arterial Hypertension Market Attractiveness Index, By Region – 2022-2032
Figure 15: North America Pulmonary Arterial Hypertension Market Value (US$ Bn) and Year-on-Year Growth, 2017-2032
Figure 16: North America Pulmonary Arterial Hypertension Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Bn
Figure 17: North America Pulmonary Arterial Hypertension Market Share, By Drug Class, 2022 & 2032
Figure 18: North America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Drug Class– 2022-2032
Figure 19: North America Pulmonary Arterial Hypertension Market Attractiveness Index, By Drug Class– 2022-2032
Figure 20: North America Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2022 & 2032
Figure 21: North America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration– 2022-2032
Figure 22: North America Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration– 2022-2032
Figure 23: North America Pulmonary Arterial Hypertension Market Share, By Type, 2022 & 2032
Figure 24: North America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032
Figure 25: North America Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration – 2022-2032
Figure 26: North America Pulmonary Arterial Hypertension Market Share, By Country, 2022 & 2032
Figure 27: North America Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 28: North America Market Attractiveness Index, By Country – 2022-2032
Figure 29: Latin America Pulmonary Arterial Hypertension Market Value (US$ Bn) and Year-on-Year Growth, 2017-2032
Figure 30: Latin America Pulmonary Arterial Hypertension Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Bn
Figure 31: Latin America Pulmonary Arterial Hypertension Market Share, By Drug Class, 2022 & 2032
Figure 32: Latin America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Drug Class– 2022-2032
Figure 33: Latin America Pulmonary Arterial Hypertension Market Attractiveness Index, By Drug Class– 2022-2032
Figure 34: Latin America Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2022 & 2032
Figure 35: Latin America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration– 2022-2032
Figure 36: Latin America Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration– 2022-2032
Figure 37: Latin America Pulmonary Arterial Hypertension Market Share, By Type, 2022 & 2032
Figure 38: Latin America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032
Figure 39: Latin America Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration – 2022-2032
Figure 40: Latin America Pulmonary Arterial Hypertension Market Share, By Country, 2022 & 2032
Figure 41: Latin America Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 42: Latin America Pulmonary Arterial Hypertension Market Attractiveness Index, By Country – 2022-2032
Figure 43: Europe Pulmonary Arterial Hypertension Market Value (US$ Bn) and Year-on-Year Growth, 2017-2032
Figure 44: Europe Pulmonary Arterial Hypertension Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Bn
Figure 45: Europe Pulmonary Arterial Hypertension Market Share, By Drug Class, 2022 & 2032
Figure 46: Europe Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Drug Class– 2022-2032
Figure 47: Europe Pulmonary Arterial Hypertension Market Attractiveness Index, By Drug Class– 2022-2032
Figure 48: Europe Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2022 & 2032
Figure 49: Europe Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration– 2022-2032
Figure 50: Europe Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration– 2022-2032
Figure 51: Europe Pulmonary Arterial Hypertension Market Share, By Type, 2022 & 2032
Figure 52: Europe Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032
Figure 53: Europe Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration – 2022-2032
Figure 54: Europe Pulmonary Arterial Hypertension Market Share, By Country, 2022 & 2032
Figure 55: Europe Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 56: Europe Pulmonary Arterial Hypertension Market Attractiveness Index, By Country – 2022-2032
Figure 57: MEA Pulmonary Arterial Hypertension Market Value (US$ Bn) and Year-on-Year Growth, 2017-2032
Figure 58: MEA Pulmonary Arterial Hypertension Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Bn
Figure 59: MEA Pulmonary Arterial Hypertension Market Share, By Drug Class, 2022 & 2032
Figure 60: MEA Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Drug Class– 2022-2032
Figure 61: MEA Pulmonary Arterial Hypertension Market Attractiveness Index, By Drug Class– 2022-2032
Figure 62: MEA Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2022 & 2032
Figure 63: MEA Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration– 2022-2032
Figure 64: MEA Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration– 2022-2032
Figure 65: MEA Pulmonary Arterial Hypertension Market Share, By Type, 2022 & 2032
Figure 66: MEA Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032
Figure 67: MEA Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration – 2022-2032
Figure 68: MEA Pulmonary Arterial Hypertension Market Share, By Country, 2022 & 2032
Figure 69: MEA Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 70: MEA Pulmonary Arterial Hypertension Market Attractiveness Index, By Country – 2022-2032
Figure 71: Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Bn) and Year-on-Year Growth, 2017-2032
Figure 72: Asia Pacific Pulmonary Arterial Hypertension Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Bn
Figure 73: Asia Pacific Pulmonary Arterial Hypertension Market Share, By Drug Class, 2022 & 2032
Figure 74: Asia Pacific Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Drug Class– 2022-2032
Figure 75: Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Index, By Drug Class– 2022-2032
Figure 76: Asia Pacific Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2022 & 2032
Figure 77: Asia Pacific Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration– 2022-2032
Figure 78: Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration– 2022-2032
Figure 79: Asia Pacific Pulmonary Arterial Hypertension Market Share, By Type, 2022 & 2032
Figure 80: Asia Pacific Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032
Figure 81: Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Index, By Route of Administration – 2022-2032
Figure 82: Asia Pacific Pulmonary Arterial Hypertension Market Share, By Country, 2022 & 2032
Figure 83: Asia Pacific Pulmonary Arterial Hypertension Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 84: Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Index, By Country – 2022-2032
Figure 85: US Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 86: US Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 87: US Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 88: US Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 89: Canada Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 90: Canada Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 91: Canada Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 92: Canada Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 93: Brazil Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 94: Brazil Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 95: Brazil Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 96: Brazil Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 97: Mexico Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 98: Mexico Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 99: Mexico Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 100: Mexico Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 101: Germany Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 102: Germany Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 103: Germany Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 104: Germany Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 105: U.K. Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 106: U.K. Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 107: U.K. Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 108: U.K. Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 109: France Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 110: France Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 111: France Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 112: France Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 113: Italy Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 114: Italy Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 115: Italy Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 116: Italy Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 117: India Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 118: India Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 119: India Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 120: India Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 121: Russia Countries Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 122: Russia Countries Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 123: Russia Countries Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 124: Russia Countries Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 125: China Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 126: China Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 127: China Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 128: China Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 129: Japan Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 130: Japan Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 131: Japan Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 132: Japan Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 133: South Korea Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 134: South Korea Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 135: South Korea Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 136: South Korea Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 137: Spain Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 138: Spain Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 139: Spain Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 140: Spain Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 141: South Africa Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 142: South Africa Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 143: South Africa Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 144: South Africa Pulmonary Arterial Hypertension Market Share, By Type, 2021
Figure 145: Saudi Arabia Pulmonary Arterial Hypertension Market Value (US$ Bn) and Forecast, 2022 - 2032
Figure 146: Saudi Arabia Pulmonary Arterial Hypertension Market Share, By Drug Class, 2021
Figure 147: Saudi Arabia Pulmonary Arterial Hypertension Market Share, By Route of Administration, 2021
Figure 148: Saudi Arabia Pulmonary Arterial Hypertension Market Share, By Type, 2021
